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Periodontal diseases (PD) affect 46% of American adults over age 30. These
diseases cause symptoms including bleeding and swelling of the gums, bone
resorption, and tooth loss, that affect quality of life and have a high economic burden.
Periodontal diseases are caused by an imbalance in the oral microbiome, from a healthy
state that contains anti-inflammatory commensals like Streptococcus gordonii and mitis, to

a diseased state that has pro-inflammatory anaerobic pathogens including
Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, and Tannerella
forsythia. The latter initiate disease progression in the oral cavity. However, it’s the host
immune response that causes a majority of the symptoms. Ideally, treatment for PD
would be approached from both sides to reduce the numbers of pro-inflammatory
bacterial cells in the oral cavity but also reduce the host immune response. A novel
therapeutic, amixicile, has been created, which specifically targets anaerobes through
the pyruvate:ferredoxin oxidoreductase (PFOR) system, the mechanism of energy
metabolism found in anaerobic organisms. Our studies show that amixicile inhibits in
vitro growth of oral anaerobes in monospecies cultures at concentrations as low as 0.5
µg/mL in broth and 1 µg/mL in biofilms, without affecting the Gram-positive
commensal species. In multispecies cultures, amixicile specifically inhibited anaerobes,
even in biofilms, with the concentration as low as 5 µg/mL in broth and 10 µg/mL in
biofilms. By not affecting the commensal bacteria, we think this treatment could
restore a healthy oral microbiome. Aside from the bacterial presence, the host
response, particularly the innate immune response is not well understood. Using a
Drosophila melanogaster infection model, we elucidated the innate immune response to
both mono- and multispecies infections. The 7-Species infection included bacteria
mentioned above and Aggregatibacter actinomycetemcomitans in order to replicate in vivolike disease conditions. We determined that both Drosophila Toll and Imd pathways,

which mimic TLR/IL-1 and TNF signaling pathways of mammalian innate immunity
respectively, respond to the 7-Species challenge. We also verified virulent bacteria in
Drosophila, including P. gingivalis and P. intermedia. Future directions include RNA
sequencing to determine the full scope of immune gene expression and using human
immune cells to further clarify the response.

Chapter 1: Introduction

Periodontal diseases
Periodontal diseases are a prevalent issue in the United States as well as in other
parts of the world. A CDC study covering 2009-2012 estimates that 46% of adults over
the age of 30 have some form of gum disease 1-3. This includes gingivitis, a reversible
disease characterized by swollen, red, and bleeding gums, and periodontitis, in its mild,
moderate, and severe forms. Periodontitis is irreversible and begins when plaque on
the teeth colonizes below the gum line, particularly when periodontal pockets form
between the teeth. This plaque is made up of oral bacteria, both commensals and
pathogens, which release toxins that irritate the gums. This stimulates the immune
response, which attempts to destroy the microbes. When the immune response fails to
eliminate the infection, additional damage to the host tissue and bone is caused by the
immune reaction. Symptoms of periodontitis progression become obvious as the gum
recedes from the teeth and the bones supporting the teeth degrade, leading to tooth
mobility and loss. In many patients, this cycle of disease is chronic due to a variety of
risk factors. Smokers, individuals who are immune-compromised, and those who do
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not practice proper oral hygiene, are at a higher risk of developing periodontal diseases
4

. Once the diseased microbiome has taken hold, it is difficult to return the oral cavity

to a healthy state.

Economic burden of periodontal diseases
Periodontal diseases and symptoms can significantly impact a person’s lifestyle.
Since approximately one out of two American adults has some level of periodontal
disease, there are tremendous costs associated with treatment and the burden of
disease 5. Globally, it is estimated that 743 million people are affected and many
countries do not have the means for treatment or prevention 6. Individuals with
periodontitis can exhibit tooth loss as well as swelling and pain in the oral cavity.
These symptoms can decrease quality of life by affecting nutrition and self-esteem. Due
to the higher percentage of disease in minority populations including HispanicAmericans and African-Americans, there is also a burden of social inequality 7.

The disease is an economic burden to the healthcare system in many countries.
In the United Kingdom, the estimated cost of morbidity was $4.6 billion in 2008 8. The
prevalence of periodontitis is higher in the elderly population and in certain minorities.
As the aging population increases, the burden will increase as well, costing the
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healthcare system ever-increasing amounts until more effective and widespread
prevention and treatment methods are determined.

Treatment of periodontal diseases
The treatments available for periodontal diseases span a wide range. For
gingivitis, typically a dental cleaning will suffice if you resume practicing proper oral
hygiene. Once periodontitis takes hold, scaling and root planing at the dentist become
necessary to successfully remove the biofilm that has spread in between the teeth and
gums. There are antibiotics that can be prescribed including clindamycin and
metronidazole to reduce the bacterial load in the oral cavity. Clindamycin is a broadspectrum bacteriostatic antibiotic that acts by protein synthesis inhibition. It is active
against aerobic and anaerobic, Gram-positive and Gram-negative bacteria, thereby
removing the normal microflora in addition to the disease-causing bacteria. This broadspectrum approach is not ideal since it has been shown that when the entire oral
microbiome is removed after the diseased state occurs, the diseased state is more likely
to return than the healthy microbiome 9,10. So broad-spectrum antibiotics are not the
best treatment for periodontitis.

Another antibiotic, metronidazole, targets anaerobic bacteria, which are
generally pathogens in periodontal diseases. It is a nucleic acid synthesis inhibitor,
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which must be reduced to be effective, and therefore only affects anaerobic organisms.
However, with this antibiotic, there’s an issue with patient compliance. It can cause
severe side effects, including nausea, diarrhea, and occasionally seizures, which reduce
the likelihood of patients completing the full course of the antibiotic 11,12. So this is also
not a strong contender to treat periodontal diseases. These are the best options on the
market, though, and without some sort of treatment, it is common to have teeth fall
out or to require surgery to repair the oral cavity. These poor treatment options and
the incredible burden of the disease are considerable reasons as to why a stronger
alternative must be found.

Oral microbiome
Under normal circumstances, the oral microbiome consists mainly of
commensal bacteria. A dental cleaning will clear out the oral cavity but soon after, the
salivary proteins begin attaching to the teeth. A variety of streptococcal spp. that are
generally considered commensals can then colonize by binding to the proteins. S.
gordonii (Sg) and S. mitis (Sm) are early colonizers of the oral cavity 13. These early
colonizers are the beginning of the plaque formation on teeth, which can be kept at a
minimum with brushing and flossing. Unfortunately, without proper oral hygiene,
more and more bacteria join the biofilm, leading to a diseased state. Late colonizers are
often pathogens, or at least opportunistic organisms. Fusobacterium nucleatum (Fn) is
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particularly notable, in that it has receptors that can bind most other bacteria that have
been found in the oral cavity. Because of this, pathogenic bacteria can easily bind and
find a niche. Once these bacteria begin joining the biofilm, a disease state is quickly
reached, ranging from gingivitis to periodontitis 14,15. Even at low abundance, some of
these pathogens can change expression of other bacteria in the biofilm 16-18.

Porphyromonas gingivalis (Pg) is considered part of the “Red Complex”, a group of
three bacteria, thought to be instrumental in periodontal diseases 19. At less than 1%
abundance, it can alter streptococcal signaling to promote its own safety 20. Other
Gram-negative anaerobic pathogens including Prevotella intermedia (Pi) and T. forsythia
(Tf) further induce the disease state by enhancing the immune response, drawing
overwhelming leukocytes to the area 21. Additionally, Aggregatibacter
actinomycetemcomitans (Aa), a Gram-positive facultative anaerobe, has also been shown
to contribute to the burden of periodontal disease. The variety of periodontal
pathogens act synergistically to further the disease state 22. The change in the oral
microbiome to a disease state increases toxin production and upregulation of other
genes that promote pathogenesis. These toxins work through the gum tissues,
activating the immune response 23. The immune system attempts to combat the
invasive microbes by drawing in neutrophils and macrophages to attempt to clear the

5

infection. However, the chronic inflammatory response is generally ineffective against
the oral biofilm, and ends up damaging the host further.

Pyruvate metabolism in aerobic and anaerobic organisms
Pyruvate metabolism is an essential pathway for survival of many organisms.
Aerobic organisms, including mammals, contain pyruvate dehydrogenase (PDH), an
enzyme that converts pyruvate into acetyl-CoA for energy. This enzyme requires an
aerobic environment, so all cells undergoing this energy metabolism must survive in
oxygenated environments. Mammalian cells and certain bacteria, including Streptococcus
spp. and A. actinomycetemcomitans utilize PDH (Figure 1). However, there is an
alternative pathway for anaerobic organisms, including many of the Gram-negative
anaerobic bacteria shown to cause periodontal diseases: P. gingivalis, P. intermedia, F.
nucleatum, and T. forsythia (Figure 1).

Pyruvate:ferredoxin oxidoreductase (PFOR) carries out the oxidative
decarboxylation of pyruvate into acetyl-CoA, without requiring oxygen. An important
part of this alternative pathway is the cofactor of the system, thiamine pyrophosphate
(TPP). Also known as vitamin B1, thiamine pyrophosphate is essential for most
organisms in that it catalyzes many biochemical reactions in cells. TPP is involved in
carbohydrate, amino acid, and energy metabolism pathways in a variety of cells 24.

6

Figure 1. Pyruvate metabolism in aerobic and anaerobic bacteria. Bacteria under
aerobic conditions have pyruvate dehydrogenase, which converts pyruvate into carbon
dioxide and acetyl-CoA. Anaerobic bacteria, however, have a different mechanism for
this conversion. Pyruvate:ferredoxin oxidoreductase works to convert pyruvate into
carbon dioxide and acetyl-CoA when under anaerobic conditions.
Adapted from: Hutcherson JA, Sinclair KM, Belvin BR, Gui Q, Hoffman PS, Lewis JP.
Amixicile, a novel strategy for targeting oral anaerobic pathogens. Scientific Reports.
2017;7. doi: 10.1038/s41598-017-09616-0.
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There is another pathway present in aerobic bacteria to carry out pyruvate metabolism
under anaerobic conditions, pyruvate formate lyase (PFL). TPP has no role in the PFL
pathway.

The PDH complex has been crystallized from both Geobacillus stearothermophilus
(G. stearothermophilus) PDH 25 (Figure 2a) and human PDH 26 (Figure 2b). There are
differences in the peptide sequences but the complex shows structural similarity. The
binding interactions are shown in Figure 2a and the amino acids involved are labeled.
TPP theoretically interacts with eight different amino acids and the manganese ion
present in the sample 25. Pyruvate was not crystallized with this complex, but it should
bind in a similar place as in Figure 2b, in the bottom left corner of the molecule.
Human PDH also has eight presumed amino acid interactions with TPP, the same ones
shown in Figure 2b, although ethyl trihydrogen diphosphate (TPW) was used for the
crystallization 26. PFOR was crystallized from Desulfovibrio africanus (D. africanus) 27
alongside TPP and pyruvate. There are seven amino acids that are potential binding
partners with TPP and an additional two with PYR (Figure 3a). On the other hand, PFL
does not use the TPP cofactor in the complex 28. There are two strong interactions with
R176 and R435 as well as a cysteine in close proximity but it doesn’t seem to bind
(Figure 3b).

8

9

Figure 2: Pyruvate dehydrogenase complex crystallized with Homo sapiens PDH
and Geobacillus stearothermophilus PDH. A) Pyruvate dehydrogenase E1 component
subunit alpha isolated from H. sapiens and expressed in E. coli (PDB ID: 3EXE) was
crystallized with thiamine pyrophosphate (TPP), glycerol (GOL), potassium ion (K),
and manganese ion (Mn). B) Pyruvate dehydrogenase E1 component subunit alpha
isolated from G. stearothermophilus and expressed in E. coli (PDB ID: 3DV0) was
crystallized with ethyl trihydrogen diphosphate (TPW), pyruvate (PYR), potassium ion
(K), and magnesium ion (Mg). TPW is structurally similar to TPP but is not active in
the complex to allow for crystallization. Alpha helices are represented in red, Beta
sheets in blue, and coils in green. Potential binding interactions with amino acids and
ions were determined in UCSF Chimera 1.12 for Mac OS X. Amino acids that may be
involved in binding interactions are labeled in cyan with the one letter designation,
amino acid number, and chain. In these peptides, carbon (C) is shown in tan, nitrogen
(N) in blue, sulfur (S) in yellow, oxygen (O) in red, phosphate (P) in orange, Mn in
purple, and Mg in light green. Labeled amino acids are as follows: A169 is an alanine
residue, E59 is a glutamic acid residue, G136, G168, G174, and G175 are glycine
residues, I143 and I144 are isoleucine residues, N196 and N202 are asparagine
residues, R90, R103, and R267 are arginine residues, V138 is a valine residue, and Y89
and Y102 are tyrosine residues.
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PFOR and PDH have some overlapping binding partners that reveal some
similarity between the complexes. The aminopyridinium ring on the left of the figure
seems to interact with glutamic acid, E59 for PDH (Figure 2a) or E64 for PFOR (Figure
3a). Interestingly, in the PFOR and PDH pathways, this interaction with glutamic acid
is essential for TPP to bend, between the aminopyridinium and thiazolium rings, into a
unique V configuration in the complex, which is unlike its configuration in other
known pathways 29. The amine group coming off of the aminopyridinium ring shows an
interaction with PYR in the PFOR crystal and we hypothesize the same would be the
case in PDH due to the similar positioning. At the top of the figures, the first
phosphate group shows two bonds, with A169 and G168 in PDH and W965 and G964
in PFOR. The glycine interaction is consistent between the crystals and the alanine and
tryptophan are both hydrophobic amino acids. Finally, the end phosphate group is
bound to uncharged asparagine, N196, for PDH or uncharged threonine, T991, for
PFOR.

The other interactions are not consistent between human PDH and PFOR. PDH
shows interactions between the end phosphate group and Y89 and R90. V138 and
G136 seem important for binding for human PDH, but not G. stearothermophilus PDH.
The end phosphate group of PFOR has interactions with S995, C840, and N996. These
differences are enough to create significantly different pockets for PYR between the

11

12

Figure 3: Pyruvate:ferredoxin oxidoreductase and pyruvate formate lyase
complexes. A) Pyruvate:ferredoxin oxidoreductase isolated from D. africanus (PDB ID:
2C42) was crystallized with thiamine pyrophosphate (TPP), pyruvate (PYR),
iron/sulfur cluster (SF4), calcium ion (Ca), and magnesium ion (Mg). B) Formate
acetyltransferase isolated from E. coli (PDB ID: 1H16) was crystallized with Coenzyme
A (CoA), pyruvate (PYR), sodium ion (Na), and magnesium ion (Mg). Alpha helices
are represented in red, Beta sheets in blue, and coils in green. Potential binding
interactions with amino acids and ions were determined in UCSF Chimera 1.12 for
Mac OS X. Amino acids that may be involved in binding interactions are labeled in cyan
with the one letter designation, amino acid number, and chain. In these peptides,
carbon (C) is shown in tan, nitrogen (N) in blue, sulfur (S) in yellow, oxygen (O) in
red, phosphate (P) in orange, and Mg in light green. Labeled amino acids are as
follows: C418 and C840 are cysteine residues, E64 is a glutamic acid residue, G964 is a
glycine residue, N996 is an asparagine residue, R114, R176, and R435 are arginine
residues, S995 is a serine residue, T991 is a threonine residue, and W965 is a
tryptophan residue.
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complexes, enough so that amixicile is able to bind in place of PYR in the PFOR
complex but is not able to in PDH. This likely also involved the R114 and T31
interactions in PFOR that are not present in PDH. G. stearothermophilus PDH (Figure
2b) is quite different from human PDH, yet still does not have many of the important
interactions that PFOR has, and it is not expected to be susceptible to amixicile.

Amixicile
Nitazoxanide (NTZ), an FDA-approved antibiotic that is currently on the
market, targets PFOR and is used to treat Cryptosporidium and Giardia parasitic
infections 30. However, it is an unpopular antibiotic due to a number of factors.
Nitazoxanide is very hydrophobic and has low efficacy. It has been shown to have high
toxicity, above 10 μM, and intraperitoneal injection in mice is lethal 31. It also causes a
variety of side effects in patients, which can include nausea, diarrhea, and vomiting,
leading to patient non-compliance.

A derivative of NTZ was created by Dr. Paul Hoffman at the University of
Virginia called amixicile (AMIX). Similarly to its parent antibiotic, AMIX targets the
thiamine pyrophosphate (TPP) vitamin cofactor, only when it is folded into the proper
configuration to fit in the PFOR complex. Both antibiotics outcompete pyruvate by
more than two orders of magnitude as the substrate in the PFOR system, which
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prevents energy metabolism 32. Typically, TPP binds pyruvate in the pathway to
complete the reaction. But this antibiotic non-competitively binds to TPP, preventing
pyruvate from binding. Since these antibiotics target the cofactor of the system, and
non-competitively at that, it is thought that this mechanism will lead to a lower
occurrence of antibiotic resistance.

Amixicile is an improvement on nitazoxanide in many ways. It has higher
solubility and higher efficacy. It has also been shown in mouse studies to have far
lower toxicity than nitazoxanide. Amixicile is well tolerated up to 200 μM in
hepatocytes and up to 300 mg/kg by oral route or intraperitoneal injection, which is 20
times better than nitazoxanide 31. Amixicile is also able to localize in areas of
inflammation, affecting the anaerobic organisms at the site, but not in other regions of
the body. As such, it has not been shown to alter the gut microbiome, even when taken
orally 32. Finally, in Clostridium (recently renamed Clostridoides) difficile mouse studies,
animals receiving oral doses of amixicile or nitazoxanide had no recurrence of
infection, while recurrence was common with vancomycin or fidaxomicin 33. Amixicile
is currently undergoing pre-clinical trials to treat C. difficile infection. Due to the
specificity of the antibiotic, and the tendency of anaerobic bacteria to cause a variety of
infections, this antibiotic could be used to treat many diseases. In this study, it is
tested on a subset of periodontal bacteria.
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Immune response
The host immune response is responsible for some of the symptoms
experienced in periodontal diseases. However, there is limited knowledge about the
specific mechanisms at play. There is an influx of immune cells to the area of disease,
responding to the bacterial infection. This response typically does not resolve, due to
the inability of the immune response to successfully combat the extensive biofilm
involved in periodontal diseases. This leads to chronic inflammation, in which
homeostasis cannot be reached. This overreaction of the immune response allows the
bacteria to gain a stronger foothold in periodontal pockets, which increase in size due
to the tissue destruction caused by immune mediators 34. Because of this, the nature of
the disease is cyclic, with both the microbiota and the immune system furthering
progression of periodontal disease.

Innate immune response in periodontal diseases
Innate immunity is the initial defense against infection. It is a multi-faceted
system that contains both physical barriers and cellular mechanisms to eliminate
microorganisms that threaten the host. The epithelium is a major component in
preventing microbes from entering the host. However, it doesn’t catch everything.
Once inside the host, immune cells can recognize pathogen-associated molecular
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Figure 4: The Imd and Toll pathways in Drosophila melanogaster. The Imd pathway
recognizes DAP-type peptidoglycan on Gram-negative bacteria through the PGRP-LC
receptor. The death domain on Imd is signaled and then activates TAB2 and TAK1. The
IKK β/γ signalosome is then activated to phosphorylate Relish. Finally, Relish
translocates to the nucleus and transcribes antimicrobial peptides (AMPs) by activating
NF-κB, including attacin, cecropin, defensin, diptericin, and drosocin. The Toll
pathway is activated by recognizing Lys-type peptidoglycan on Gram-positive bacteria
through a proteolytic cascade that cleaves Spätzle. Toll activates MyD88, Tube, and
Pelle in order to degrade Cactus, which allows Dif and Dorsal to localize to the
nucleus, activating NF-κB, and upregulating transcription of antimicrobial peptides
including cecropin, defensin, drosomycin, and metchnikowin. Canton-S and Y,w are
two commonly used wild type flies that have normal functioning Toll and Imd
pathways. Additionally, we used three mutant strains, where proteins throughout
these pathways are inactivated, shown underlined in the figure. The Spz mutant has
defective Spätzle protein and the Imd mutant has a defect in Imd. The Key mutant has
inactive Kenny protein, which helps make up the IKK signalosome.
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patterns (PAMPs) to mark the intruder for destruction. A variety of Toll-like receptors
(TLRs) can recognize lipopolysaccharide, peptidoglycan, bacterial flagella, and more 35.
A few have been shown to specifically recognize periodontal pathogens. TLR2 can
recognize components of P. gingivalis, P. intermedia, and T. forsythia, among others 36,37.
TLR4 can identify lipopolysaccharides on A. actinomycetemcomitans 23,37. Intracellular
TLR9 identifies P. gingivalis and A. actinomycetemcomitans by unmethylated CpG motifs 21.
The mammalian TLRs are actually named after Drosophila Toll, which recognizes lysinetype peptidoglycan found on Gram-positive organisms. Mammalian TLRs can initiate
many different pathways that lead to pathogen elimination. The most relevant here is
the activation of NF-κB, which produces pro-inflammatory cytokines.

Pro-inflammatory cytokines IL-1 and TNF have been shown in periodontal
disease to contribute to bone resorption, loss of connective tissue attachment, and
amplification of the immune response 38. This includes much of the damage that is
typically seen in periodontal disease. IL-1 deficient mice have an attenuated immune
response but generally develop normally 39. However, they are more susceptible to
certain types of infection, including endodontic, which can become lethal 40. TNF-α and
TNF-β attach to similar receptors but the receptors have different cytoplasmic
domains, allowing differential signaling 41. TNF has been shown to play a role in
resistance to bacterial infection and in activating inflammatory molecules.
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The innate immune response consists of both cellular and acellular components.
Quite a bit of work has gone in to research on the cellular portion, including looking at
neutrophils, macrophages, and natural killer cells 42. In healthy gingiva, there are low
levels of macrophages but the number increases in gingivitis or chronic periodontitis
patients 43. CD68-positive macrophages have been found in periodontal pockets and
have been positively correlated with collagen breakdown in clinical trials 44-46. It is
thought that P. gingivalis infection affects TLR2 signaling in macrophages so that they
are not eliminated but also they still get necessary nutrients. This is supported by
studies showing that macrophage depletion leads to less inflammatory bone loss and
lower numbers of P. gingivalis 47,48.

Neutrophils are known to be the most common leukocyte in the blood,
comprising 65-75% of white blood cells 49. Neutrophils undergo diapedesis, or
transmigration through the vessel walls to the site of inflammation. They can kill
invading microbes by phagocytosis or by releasing toxic products including
antimicrobial peptides (AMPs) 50. They can release cytokines and chemokines that have
pro-inflammatory, anti-inflammatory, or regulatory effects throughout the system 51.
Deficiencies that cause less neutrophils, adhesion, or transmigration all lead to more
severe periodontitis. However, excess neutrophils have been linked to bone resorption,
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indicating that the homeostasis of neutrophils is essential to health, rather than their
presence or absence 52,53. It is thought that the immune and inflammatory responses
initiated by neutrophils are unable to clear periodontitis-associated bacteria, which can
generally avoid neutrophil-mediated killing 54. P. gingivalis works by activating TLR2 and
complement, which actually degrades TLR2 adapter MyD88, effectively inhibiting that
branch of the immune response 55.

Acellular components, such as complement, also have been found to play a role
in periodontal diseases. Significantly higher levels of complement cleavage products are
found in patients with periodontitis than in healthy patients, particularly in the
inflamed gingiva 56-58. Complement also plays a key role in linking the innate and
adaptive immune responses 59. AMPs are another acellular component of the innate
immune response. A variety of AMPs with different functions have been found in saliva
and gingival fluid. These are categorized into cationic peptides, bacterial agglutination
and adhesion, metal ion chelators, peroxidases, protease inhibitors, and those with
activity against cell walls 60. Lactotransferrin, a metal ion chelator has been shown to
have higher expression in patients with severe periodontitis 61. Cathelicidin (LL-37) has
been studied in many different aspects, identifying that the levels are also higher in
chronic periodontal patients and that the levels correlate to the probing depth, plaque
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index, bleeding, and more 62. It is capable of neutralizing LPS on Gram-negative
bacteria but is partially inhibited by saliva 63.

Cathelicidin deficiency has been found in a number of diseases including
Morbus Kostmass disease and Haim-Munk syndrome. The decrease in α-defensins, a
class of AMPs, contributes to severe neutropenia and increased periodontitis 64,65. In a
disease called Papillon-Lefèvre, there is a deficiency in cathepsin C 66. Cathepsin C
activates serine proteases in order to activate parts of the immune response, including
phagocytic cells. With this deficiency, cathelicidin cannot be properly processed and
patients have severe destructive periodontitis. Natural killer cells have been reported as
dysfunctional in the disease, indicating they could be a component of an effective
immune response involved in periodontal diseases 66. In patients with SCID and other
combined immunodeficiencies, a predisposition to periodontal disease can occur due to
cytokine dysregulation 67. Both the TNF and IL-1 pathways, the two innate immune
pathways focused on in this study, are affected by cytokine dysregulation.

Some research has been done on the role of AMPs in periodontal diseases but
there is still much to learn. Given the direct connections of AMP deficiencies with
innate immune disorders that seem to allow more severe periodontitis, we looked at
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the similarities between Drosophila innate immunity and mammalian innate immunity
to elucidate specific mechanisms behind the periodontitis sensitivity.

Using Drosophila melanogaster to study periodontal pathogens
Drosophila melanogaster (Dm) is used extensively as a model organism, particularly
to study bacterial-host interactions. However, studying infections of anaerobic bacteria
is very recent. Drosophila infected with P. gingivalis was investigated at Ohio State
University to determine which common virulence factors were involved in
pathogenesis. The capsule, fimbriae, and gingipains were all shown to be important for
pathogenesis in the flies 68. This corresponds to factors that affect pathogenesis in
mammals, indicating that fruit flies could be a relevant model organism. There are
many more periodontal pathogens to study, particularly since periodontal diseases are
multifactorial and involve many pathogenic species.

Drosophila immunity has many similarities to mammalian innate immunity.
While the Toll signaling pathway is involved in a wide variety of processes, including
dorso-ventral embryonic patterning and heart and muscle development, this study will
only focus on its role in innate immunity. The Toll pathway is activated in response to
Gram-positive bacteria, due to the recognition of Lys-type PGN (Figure 4). Toll has
many orthologs, including Toll-like receptors 1-10 in humans. Serine proteases
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recognize the PAMPs and cleave Spatzle, which activates Toll. Toll then signals
through MyD88, Tube, and Pelle in order to degrade Cactus. MyD88 is homologous to
the adaptor protein similarly named in humans, while Tube is orthologous to histone
H3 associated protein kinase. Pelle is a tyrosine kinase that resembles interleukin 1
receptor associated kinases (IRAK1-4). Cactus is an NF-κB inhibitor, similar to the
NFKBI family in humans. With Cactus degraded, the inhibition is removed, and Dif
and Dorsal, both NF-κB subunits, are able to translocate to the nucleus. NF-κB is
activated and transcription of Toll-controlled antimicrobial peptides (AMPs) is
upregulated. AMPs that respond to Gram-positive infections in this fashion include
Cecropin, Defensin, Drosomycin, and Metchnikowin. As evidenced by the orthologs,
the Toll pathway in Drosophila and the TLR/IL-1 signaling pathways in humans, are
very similar, and therefore, we can extrapolate information about the activation of
these pathways in humans by looking at the pathway activation in Drosophila.

The Imd pathway, among other functions, recognizes Gram-negative bacteria
through the pathogen-associated molecular pattern (PAMP), DAP-type PGN. Similarly
to the mammalian TNF receptor 1 signaling pathway, a transmembrane receptor
recognizes the bacteria and signals Imd, which is orthologous to the p53-induced death
domain protein. The death domain of Imd, through FADD, then activates TAB2 and
TAK1. TAB2 is a homolog of MAP3K binding proteins and TAK1 is an ortholog of

24

many MAP kinase kinase kinase proteins in humans. These signal the IKK β/γ
signalosome, which includes Key. These have homology to IKBK subunits B, E, and G.
The signalosome acts to cleave the ankyrin repeat to phosphorylate Relish, which
permits it to enter the nucleus, becoming active NF-κB, but in this case transcribing
anti-Gram-negative AMPs such as Attacin, Cecropin, Defensin, Diptericin, and
Drosocin. Finally, transcribed AMPs are able to recognize the bacterial target for which
they were activated and mark them for destruction. The mechanisms of action of these
AMPs have been determined. Attacin works by preventing outer membrane synthesis 69
while Cecropin and Defensin create ion channels in the cytoplasmic membrane 70,71.
Diptericin and Drosomycin cause lysis of the cell by affecting the cytoplasmic
membrane 72,73 and Drosocin interferes with DnaK 74. The mechanism of action for
Metchnikowin is unknown. Again, this pathway is very similar to mammalian immune
pathways, indicating the potential for relevant conclusions to be drawn from Drosophila
experiments.

The research into antimicrobial peptides in Drosophila melanogaster is far from
complete. Infection of Drosophila by anaerobic bacteria is uncharted territory.
Additionally, there have been very few studies that look at polymicrobial infection in
Drosophila. The first was in 2008, when a co-infection model was created to look at
interactions between Pseudomonas aeruginosa and oropharyngeal flora in Cystic Fibrosis
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75

. The fruit flies were co-infected with P. aeruginosa and one bacterial strain found from

oropharyngeal patient isolates by ingestion. P. aeruginosa was able to establish a chronic
infection and stimulated transcription of Cecropin, Diptericin, and Drosomycin 76. The
40 isolates it was co-infected with either inhibited, increased, or synergistically
activated AMP expression. The other study was also about Cystic Fibrosis, using P.
aeruginosa co-infected with S. parasanguinis. Both of these only looked at two bacterial
strains colonizing the same system. The six- and seven-species cultures that I use in
my experiments are unprecedented in the Drosophila model. The multispecies infection
is much more similar to in vivo periodontal disease than looking at only monospecies.
Other systems including Caenorhabditis elegans have actually been used to create an in
vivo biofilm but the research into Drosophila still has a ways to go before that 77. But we
think that this multispecies infection model could pave the way for a polymicrobial
disease research in Drosophila.

Research objectives
The current treatments for periodontal diseases are limited, despite the high
economic burden and the increasing population with some level of periodontal disease.
The extent of the role that the immune system plays in the disease manifestation is
also still poorly understood. The goal of the amixicile studies was to determine the
susceptibility of periodontal pathogens to this novel therapeutic. We found that
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amixicile was as effective as the antibiotics currently prescribed when in broth cultures.
It also showed the ability to inhibit biofilm growth. The work in Drosophila melanogaster
was meant to further elucidate the innate immune response that reacts to infection
with periodontal pathogens. The differential regulation of antimicrobial peptides
produced through the Drosophila immune pathways sheds some light onto the
overactive response that has been shown to contribute to periodontal disease
symptoms.
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Chapter 2: Materials and Methods

Culture conditions for bacterial strains
A selection of bacteria commonly found in the oral cavity were used in this
study. Bacterial strains Porphyromonas gingivalis 33277, Aggregatibacter
actinomycetemcomitans 33384, Fusobacterium nucleatum 25586, Tannerella forsythia 43037,
Streptococcus gordonii 10558, and Streptococcus mitis 49456 were acquired from ATCC.
Additionally, Porphyromonas gingivalis W83 78-80 and both strains of Prevotella intermedia,
17 81 (Leung Lab) and OMA 14 82 had been previously acquired from other laboratories,
as cited. All strains were cultured in a Coy anaerobic chamber (Ann Arbor, MI) with an
artificial atmosphere (80% N, 10% H, and 10% CO2) at 37°C. Microbial strains were
maintained on Trypticase Soy Agar Plates with 5% Sheep Blood (Thermo Fisher
Scientific, BD 221261). Overnight cultures for experimentation were grown in brain
heart infusion (BHI) broth media. Additionally, 5 µg/mL hemin (Sigma H-2250) and
0.2 µg/mL menadione (Sigma, V-3501) were added to the BHI for all bacteria. 5% Fetal
Bovine Serum (FBS) (where from) and 1 µg/mL N-Acetylmuramic acid (Sigma, A3007) were added only to Tannerella forsythia cultures to promote growth. All media
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was placed in the anaerobic chamber at least 12 hours prior to experimentation to
equilibrate.

Culture conditions for Drosophila melanogaster strains
Drosophila melanogaster strains Canton-S, Imd-/-, H1, H2, Spz-/-, Y,w, and Key-/were kept in culture vials containing cornmeal, yeast, and sugar media (Grotewiel Lab)
at 25°C. The Canton-S wild type strain came from Carolina Biological Supply Company
and Imd-/- (P{Dipt2.2-lacZ}1; b* pr* imd1) was acquired from Bloomington Drosophila
Stock Center. The Igboin Lab graciously provided the Y,w (yw DD1; cn bw), Key-/- (yw
DD1; cn bw key1), H1 (TM3 Sb Ser/spzrm7), and H2 (TM3 Sb Ser/spz197) strains. The
two heterozygous Spz mutants, H1 and H2, were crossbred to create a homozygous
Spz-/- mutant for use in experiments. Three-five day old female flies were used for all
experiments.

Bacterial growth studies
Cultures grown on blood agar plates were collected to start broth cultures.
These were grown anaerobically at 37°C for 48 hours and used to inoculate an
overnight (O/N) culture. BHI broth (Fisher Scientific, B11059) was aliquoted and
supplemented with varying concentrations of amixicile (0, 0.5, 1, 2, 3, 5, or 10 µg/mL).
Clindamycin (Millipore Sigma, C2250000), a broad-spectrum antibiotic that inhibits
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growth of all the bacteria in this study, at the highest dose (10 µg/mL) was used as a
control. The O/N cultures were used to inoculate the BHI broth at OD600 0.1. Bacterial
growth was measured by absorbance at OD600 at 24 hours. Additionally, OD600 was
measured every 24 hours up to 96 hours for Pg and Sg cultures. Multispecies cultures
were inoculated with each bacterial strain at OD600 0.05 simultaneously. These were
then incubated with either amixicile or metronidazole at 10 µg/mL for 48 hours. For
more in vivo-like conditions, 10% filtered human saliva (Lee Biosolutions, 991-05) or
10% filtered human serum (Valley Biomedical, HS1021) was added to the media to
determine whether they affected the efficacy of the antibiotic.

Drosophila melanogaster injections bacterial counts
Wild type (Canton-S) female flies were injected with bacterial cultures, either
mono- or multispecies mixtures, or BHI. Five flies from each condition were collected
at one hour. The flies were washed with ethanol and ground with a Kontes Pellet
Pestle Grinder (Kimble Chase, 749521-1500) in BHI. Each sample was diluted 1:10,
1:100, and 1:1000 and plated on blood agar plates. These were grown for five days
anaerobically and then counted to determine CFU/fly. Triplicate plates were used to
calculate CFU/fly and standard deviation. Uninfected control flies were used to
normalize the data.
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Drosophila melanogaster survival study
This experiment was done according to a previously published protocol 68.
Twenty flies of each strain (Canton-S, Imd-/-, Spz-/-, Y,w, Key-/-) per experimental
condition (BHI, P. gingivalis 77, P. intermedia OMA 14, A. actinomycetemcomitans, F.
nucleatum, T. forsythia, S. gordonii, S. mitis, 6-Species mix, 7-Species mix) were separated
to determine Drosophila survival. O/N cultures of each bacterium were spun down and
resuspended in anaerobic BHI to reach a final concentration of OD600 3.0/mL in 200 µL.
For the multispecies cultures, the total concentration was still OD600 3.0/mL in 200 µL.
So, OD600 of 0.5 or 0.43 were used per bacteria for the 6-Species (P. gingivalis 77, P.
intermedia OMA 14, A. actinomycetemcomitans, F. nucleatum, T. forsythia, S. gordonii) and 7Species (P. gingivalis 77, P. intermedia OMA 14, A. actinomycetemcomitans, F. nucleatum, T.
forsythia, S. gordonii, S. mitis) cultures, respectively. The flies were anesthetized with
carbon dioxide and a sterile 30-gauge needle was dipped in BHI, as the negative
control, or in a mono- or multispecies bacterial culture. The needle was then gently
inserted into the right dorsal thorax, enough to just get the tip of the needle through
the cuticle of the fly. Dipping the needle between each injection, this system was
repeated for each fly under each condition. Different vials were used to store each set
of flies at 30°C. After one hour, to allow the flies to awaken, the surviving flies were
counted as the 0 hour time point. The number of surviving flies was counted every 12
hours for the duration of the experiment, seven days.
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Drosophila melanogaster immune response study
Forty flies of each strain (Canton-S, Imd-/-, Spz-/-, Y,w, Key-/-) per experimental
condition (BHI, 7-Species) were separated in order to determine the Drosophila innate
immune response to the mixed bacterial culture. The 7-Species culture was mixed and
the injections were performed according to the above specifications. Different vials
were used to store each set of flies at 30°C. Five flies were collected from each
condition at 1 hour, 2 hours, and 24 hours post-infection for genomic DNA isolation.
Ten flies were collected from each condition at 2 hour and 24 hours post-infection for
RNA isolation.

Saliva preparation for biofilm experiments
10 mL of human saliva (Lee Biosolutions, 991-05-P) was diluted 1:2 in PBS. It
was then centrifuged for 15 minutes at 5,500 rpm at 4°C. The supernatant was moved
to a fresh tube and an EDTA-free Protease Inhibitor Cocktail Tablet (Millipore Sigma,
11836170001) was thoroughly mixed in. The solution was then filter-sterilized with a
0.22 µm filter (Millipore Sigma, SLGP033RS). An appropriate amount of filtered saliva
was used to coat wells of Falcon Tissue Culture-Treated Plates (Thermo Fisher
Scientific, 08-772-1H, 08-772-33, 08-772-3A) for 30 minutes at 37°C. Wells were then
washed 3x using sterile PBS before experimentation.
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Crystal violet biofilm assays
Monospecies biofilm formation was measured using crystal violet staining.
Overnight bacterial cultures were grown and then diluted to an OD600 0.1 with fresh
BHI. 1 mL of this dilution was transferred to each well of a 24-well saliva-coated plate
and then incubated for 24 hours anaerobically. The plates were washed with PBS and
BHI containing 0, 5, or 10 µg/mL amixicile was added for an additional 24 hours. PBS
was again used to thoroughly wash the wells, which were then stained with crystal
violet for 15 minutes. Washes were repeated and the plates were dried completely.
Finally, 30% acetic acid was added to the wells and absorbance at OD550 was read on a
BioTek Synergy H1 Hybrid Plate Reader. T. forsythia, due to its slow growth rate, was
grown for 96 hours, with amixicile added for the final 24 hours.

Multispecies biofilm experiments
Saliva prepared according to the procedure above (conditioned saliva) was added
to 12-well tissue culture-treated plates. PBS was used to wash residual saliva from the
wells. An overnight culture of S. gordonii was diluted to OD600 0.05 in BHI and added to
each well. Wells were washed with PBS at 24 hours. Overnight cultures of P. gingivalis,
P. intermedia, A. actinomycetemcomitans, F. nucleatum, and T. forsythia were each diluted to
OD600 0.05 and combined in BHI. For three additional days, fresh media was added

33

every 24 hours to the wells after washing. On day four, fresh media was added that
either contained no antibiotic or was supplemented with 10, 20, or 50 µg/mL amixicile
or metronidazole. Every 24 hours, fresh antibiotic-containing media was added until
day nine. Wells were washed and the biofilm was harvested for DNA isolation and
qPCR analysis.

Genomic DNA isolation from bacterial cultures
Genomic DNA was isolated from the mono- and multispecies cultures above. An
OD600 1.0 from each culture was spun down and the pellets were resuspended in 50
mM EDTA. 10 mg/mL lysozyme (Sigma, L6876) and 100 U/mL mutanolysin (Sigma,
M9901) were added to the suspension and incubated for 1 hour at 37°C. The published
protocol for the Wizard Genomic DNA Purification Kit (Promega, A1125) was used to
isolate genomic DNA. In the last step, the DNA pellets were rehydrated O/N at 4°C.
The concentration was measured by nanodrop.

Genomic DNA isolation from Drosophila melanogaster
Genomic DNA was isolated from five flies for each condition. Using a Kontes
Pellet Pestle Grinder (Kimble Chase, 749521-1500), the flies were ground in 500 µL of
PBS. After transferring the mixture into Lysing Matrix B tubes (MP Biomedicals, 6911500), they went through bead beating at 6 m/s, MP: 24x2, for 45 seconds in the
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FastPrep-24 (MP Biomedicals, 116004500). These were then incubated for 30 minutes
in a 42°C water bath. After incubation, the published protocol for the Wizard Genomic
DNA Purification Kit (Promega, A1125) was followed for steps Lyse Cells, Protein
Precipitation, and DNA Precipitation and Rehydration. However, the rehydration was
done in 50 µL of water at 4°C O/N. The samples were measured by nanodrop and
diluted for qPCR to 5 ng/µL.

RNA isolation and cDNA synthesis from Drosophila melanogaster
RNA was isolated from ten flies for each condition. The flies were thawed and a
Sorvall Legend Micro 21R Microcentrifuge (Thermo Scientific, 75002490) was preset
to 4°C. RNaseZap (Ambion, AM9780, AM9782) and 70% ethanol were used to clean
the bench top along with tools and reagent bottles. A Kontes Pellet Pestle Grinder
(Kimble Chase, 749521-1500) was used to completely grind the flies in 500 µL of
Buffer RLT. The entire amount was transferred into Lysing Matrix B tubes (MP
Biomedicals, 6911-500). To these tubes, 500 µL of Acid Phenol:Chloroform (Ambion,
AM9722) was added. These were then placed in the FastPrep-24 (MP Biomedicals,
116004500) in order to bead beat the samples at 6 m/s, MP: 24x2, for 45 seconds.
These tubes were placed on ice to cool for 5 minutes and then centrifuged for 10
minutes at 4°C at maximum speed. The top layer from centrifugation was transferred
to a sterile microcentrifuge tube. This layer was mixed thoroughly with 500 µL of
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100% ethanol and the solution, 700 µL at a time, was moved to an RNeasy Mini Spin
Column. The columns were spun at maximum speed for 30 seconds. A master mix was
created from 70 µL of Buffer RDD and 10 µL of DNase enzyme, per sample, from the
RNase-Free DNase Kit (Qiagen, 79254). Onto each column, 80 µL of the mixture was
pipetted and incubated at room temperature for 30 minutes. The Quick-Start protocol
for the RNeasy Mini Kit (Qiagen, 74106) was followed from this point on. However, in
the final elution, only 25 µL of RNase and DNase-Free water was used. Subsequently,
further DNase treatment was performed using the DNA-free DNA Removal Kit
(Ambion, AM1906). The SensiFAST cDNA Synthesis Kit (Bioline, BIO-65053) and the
associated protocol were then used for the samples. The resulting cDNA was diluted to
100 ng/µL to perform qPCR.

qPCR of Drosophila melanogaster immune response genes
All qPCR was performed in MicroAmp Optical 96-Well Reaction Plates (Applied
Biosystems, N8010560) on the QuantStudio 3 machine (Applied Biosystems by
Thermo Fisher Scientific, A28132). Plates were run according to the following
protocol: 95.0°C/20 sec, 40x [95.0°C/1 sec, 60.0°C/20 sec]. The expression of the
following immune response genes was investigated using the primer sets shown in
Table 1. β tubulin was used as an endogenous control. The Ct (cycle threshold) values
were determined and converted to absolute fold change.
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Table 1: Primer sets for immune response genes and housekeeping gene, β
tubulin.
Forward Primer
Reverse Primer
Attacin
TAAGCAAGGCCGTTGGAACT ATTGTTGTAGCCCAGGGTGG
Cecropin
TCTGGCCATCACCATTGGAC CAGTCCCTGGATTGTGGCAT
Defensin
CAGCCAGTTTCCGATGTGGA AGAGTAGGTCGCATGTGGCT
Diptericin
ATTGGACTGGCTTGTGCCTT
GGGAGCATATGCCAGTGGTT
Drosocin
GCTGCTTGCTTGCGTTTTTG
GTCAGGTGATCCTCGATGGC
Drosomycin
GTCTGGGACAACGAGACCTG CTTCGCACCAGCACTTCAGA
Hop
CAAGGATGTGTCCGTGACGA GCCGTACAGCTTGAGGAACT
Imd
TCTTGGCATGTCGGAAGGAC AGCTTCGAATCCACTGGAGC
Metchnikowin
CACGGCTACATCAGTGCTGG ACCCGGTCTTGGTTGGTTAG
Toll
GGTCTTTTGGCCGGTTTCAC
TTGTCCAGATCCTCCTCCGT
β tubulin
TGTTACGCCCGAATTTCCGA GCGTCGGTGTAATTGCAGAC

Table 2: Primer sets for 16S gDNA for bacterial species in the multispecies
infections.
Orientation Sequence (5’-3’)
Porphyromonas gingivalis W83
Forward
ACGGGAATAACGGGCGATAC
Reverse
CTCAGGTTTCACCGCTGACT
Porphyromonas gingivalis 33277
Forward
GGTGCGTAGGTTGTTCGGTA
Reverse
TCCTGTTTCATACCCACGCC
Prevotella intermedia
Forward
CCATCAGGTTATGCTGGGCA
Reverse
GTTGCAGACCTCAGTCCGAA
Aggregatibacter actinomycetemcomitans Forward
GTGGGGAGCAAACAGGATTAG
Reverse
CCTAAGGCACAAACCCATCTC
Fusobacterium nucleatum
Forward
TCGTGTCGTGAGATGTTGGG
Reverse
TCACGGCTTTGCAACTCTCT
Tannerella forsythia
Forward
AGGATGACTGCCCTATGGGT
Reverse
AAGCGACAAACTTTCACCGC
Streptococcus gordonii
Forward
GCAATTGCACCACTACCAGA
Reverse
TGCTCGGTCAGACTTTCGTC
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qPCR of bacterial genomic DNA
Genomic DNA was used to quantify the amount of each bacterial species
present in broth and biofilm samples. 1 µL of purified DNA and species-specific 16S
primers were used with Fast SYBR Green Master Mix (Thermo Fisher Scientific,
4385616). qPCR was performed on a 7500 Fast Real-time PCR machine (Thermo
Fisher Scientific, 4351106) with the following cycle conditions: 95.0°C/20 sec, 40x
[95°C/3 sec, 60.0°C/30 sec]. The presence of bacteria was investigated using the
primer sets shown in Table 2. The Ct (cycle threshold) values were determined and
converted to absolute fold change.

LIVE/DEAD staining
Overnight cultures of P. intermedia 17 were diluted to OD600 0.5 in BHI
containing 0, 1, 5, or 10 µg/mL amixicile. Heat and 10 µg/mL clindamycin or
metronidazole were used as positive controls. At 0, 2, and 24 hours post-infection, 50
µL of each sample was transferred to a 96-well plate and mixed thoroughly with 50 µL
LIVE/DEAD Baclight Bacterial Viability Kit (Thermo Fisher Scientific, L7007)
components, according to the manufacturer’s protocol. Plates were incubated in the
dark for 15 minutes anaerobically. Fluorescence microscopy was used to visualize cells
on the ImageXpress Micro XLS (Molecular Devices), with images taken at 60X. Live
and dead cells that were present in the view (Figure 12) were manually counted to

38

determine the total number of cells and the percent live/dead. A representative portion
of each image is shown in Figure 12.

Statistical analysis
Graphpad Prism 5.0 was used to analyze data by ANOVA. All experiments were
performed in triplicate, unless otherwise stated. p-values for statistical significance are
as follows: *p<0.033, **p<0.002, and ***p<0.001 compared to the untreated control.
When noted, Kaplan-Meier curves were used to display survival over time using SAS
EG v.6.1. Survival was compared across bacterial infections using Cox Proportional
Hazards analysis. A significance level of 0.05 was used for analyses.

39

Chapter 3: The effect of amixicile on oral microbes

Introduction
Pathogenic species in the oral cavity are typically Gram-negative anaerobes 18.
These bacteria rely on PFOR for energy generation and therefore, survival. Amixicile
specifically targets the PFOR pathway by binding to TPP, the cofactor of the system,
with a higher affinity than pyruvate 83. Due to this MOA, amixicile should be able to
selectively target anaerobic bacteria in simulated multispecies broth and biofilm
models to mimic the diverse collection of bacteria found in the oral cavity. By
selectively decreasing the anaerobic bacteria, which are often pathogenic or
opportunistic, amixicile could shift the diseased oral microbiome back to a healthy
state. We tested amixicile alongside metronidazole, another selective antibiotic, which
is already used in the clinic to treat periodontal diseases. We show that amixicile is at
least as effective as metronidazole at targeting anaerobic organisms, even in
multispecies cultures. Given that metronidazole has extensive side effects when
prescribed 11,12, these results indicate that amixicile could be a viable alternative
treatment for those suffering from periodontal diseases.
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Figure 5: KEGG pathway map of pyruvate metabolism. This map shows all genes
that are currently known to be involved in pyruvate metabolism. The red box
encompasses the known pathways to specifically convert pyruvate to acetyl-CoA. Three
major pathways are used here, pyruvate formate lyase, pyruvate dehydrogenase, and
pyruvate:ferredoxin oxidoreductase.
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Figure 6: KEGG pathway maps of pyruvate metabolism for a variety of aerobic
and anaerobic bacteria. These are subsets of the larger pyruvate metabolism map in
Figure 5. The area inside the red box is represented for the bacteria used in these
studies as well as additional bacteria and model organisms for comparison. Green
boxes indicate that the gene has been found and annotated in that particular species.
The PFL pathway is represented by gene 2.3.1.54. The PDH pathway is represented by
genes 1.2.4.1 and 2.3.1.12. The PFOR pathway is represented by genes 1.2.7.1 and
1.2.7.-.
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Results
Pyruvate metabolism varies between aerobic and anaerobic organisms.
Aerobic organisms rely on PDH for pyruvate metabolism under aerobic
conditions, and often have PFL as a backup system in anaerobic conditions. Anaerobic
organisms, however, use PFOR for pyruvate metabolism. In order to see if there was
any unexpected overlap, where anaerobic organisms may have PDH or PFL, or aerobic
have PFOR, I analyzed the KEGG database. This is an extensive database of what genes
have been found in different organisms and what pathways they are involved in. The
pyruvate metabolism map is extensive but in this case, I only focus on the oxidative
decarboxylation of pyruvate into acetyl-CoA. A. actinomycetemcomitans, S. gordonii, and S.
sanguinis appeared as expected, containing both the PDH pathway and the PFL pathway
but not having the genes required for PFOR (Figure 6). D. melanogaster and H. sapiens
appear to only contain PDH and not have a backup system for anaerobic conditions
(Figure 6). This makes sense since neither can survive for any significant length of time
anaerobically. P. gingivalis, P. intermedia, and T. forsythia are three species commonly
found in the oral cavity in periodontal disease and are all obligate anaerobes. These
organisms all clearly contain the PFOR pathway but not the PDH or PFL pathways
(Figure 6). Helicobacter pylori, which has been shown to be susceptible to amixicile, and
Desulfovibrio africanus, from which PFOR was crystallized, both follow the same pattern.
F. nucleatum, on the other hand, seems to have both PFOR and PFL. In recent studies of
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Figure 7. Amixicile inhibits growth of oral anaerobic bacteria. Bacterial strains: (a)
P. gingivalis W83, (b) P. intermedia OMA 14, (c) A. actinomycetemcomitans 33384, (d) F.
nucleatum 25586, (e) T. forsythia 43037, and (f) S. gordonii 10558 were cultured without
or with amixicile (0.5, 1, 2, 3, 5, and 10 µg/mL) in BHI. OD600 was measured at 24
hours. Clindamycin (10 µg/mL) was used as a positive control for growth inhibition.
(g) P. gingivalis W83 and (h) S. gordonii were grown in BHI containing no antibiotic or
1, 5, or 10 µg/mL amixicile. Growth was measured every 24 hours over 96 hours.
Results are shown as mean ± SD. Statistical analysis was done by ANOVA. *p<0.033,
**p<0.002, and ***p<0.001 compared to the untreated control.
g&h) Adapted from: Hutcherson JA, Sinclair KM, Belvin BR, Gui Q, Hoffman PS, Lewis
JP. Amixicile, a novel strategy for targeting oral anaerobic pathogens. Scientific Reports.
2017;7. doi: 10.1038/s41598-017-09616-0.
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Thermoanaerobacterium saccharolyticum, which also contains both, it was determined that
the roles are different but slightly redundant 84. They found that PFOR was crucial for
pyruvate dissimilation, while PFL focused on biosynthesis. When PFOR was deleted,
PFL was only partially able to compensate for the loss 84. Finally, C. difficile contains
both PFOR and PFL and also contains the dihydrolipoamide acetyltransferase from the
PDH pathway. Since the rest of the PDH complex is missing, it is likely that the
dihydrolipoamide acetyltransferase is useful in a different context. So there is no
overlap seen between PFOR and PDH, although either can be found with PFL.

Amixicile shows dose dependent inhibition of anaerobic bacteria.
To initially test the efficacy of amixicile, overnight broth cultures of periodontal
bacteria were grown. P. gingivalis W83, P. intermedia OMA 14, A. actinomycetemcomitans,
F. nucleatum, T. forsythia, and S. gordonii were centrifuged and resuspended to OD600 0.1
in BHI that was supplemented with 0, 0.5, 1, 2, 3, 5, or 10 µg/mL amixicile. 10 µg/mL
clindamycin, often prescribed to clinically treat periodontal diseases, was used as a
control. Bacterial growth was measured at 24 hours after anaerobic incubation to
determine the effect of amixicile on each strain. T. forsythia was grown for 96 hours due
to its slow rate of growth. Clindamycin successfully inhibited all bacteria, as expected.
1 µg/mL or more of amixicile was sufficient to significantly inhibit growth of Gramnegative anaerobes, though P. intermedia seemed more resistant than other bacteria

47

Figure 8. Amixicile inhibits oral anaerobic bacteria in multispecies broth culture.
Overnight bacterial cultures were each diluted to OD600 0.05 and then combined in
BHI. Broth cultures were grown at 37°C in media that was unsupplemented or had 10
µg/mL amixicile or metronidazole. At 48 hours, 1 OD600 was harvested and quantified
by qPCR. Ct values were converted to absolute fold change, where any positive change
was represented as values more than +1 and any negative change was proportionally
converted to values less than -1. Results are shown as mean ± SD compared to the
untreated control from triplicate experiments. Statistical analysis was done by ANOVA.
*p<0.033, **p<0.002, and ***p<0.001 compared to the untreated control. This figure
is based on data acquired by Dr. Justin Hutcherson.
Adapted from: Hutcherson JA, Sinclair KM, Belvin BR, Gui Q, Hoffman PS, Lewis JP.
Amixicile, a novel strategy for targeting oral anaerobic pathogens. Scientific Reports.
2017;7. doi: 10.1038/s41598-017-09616-0.
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(Figure 7). F. nucleatum and T. forsythia were particularly susceptible, showing almost no
growth even at the low dose of 0.5 µg/mL. S. gordonii was unaffected by amixicile while
A. actinomycetemcomitans showed slight reduction in growth at 5 and 10 µg/mL. Both
bacteria use pyruvate dehydrogenase for pyruvate metabolism and do not contain the
gene that encodes pyruvate:ferredoxin oxidoreductase. Additionally, long-term
inhibition was observed over 96 hours for P. gingivalis but not for S. gordonii. In short,
amixicile at 1-2 µg/mL sufficiently reduced bacterial growth up to 96 hours of
anaerobes as well as clindamycin. PFOR-lacking bacteria, particularly S. gordonii, were
not inhibited.

In multispecies broth cultures, amixicile specifically inhibits anaerobic bacteria.
Monospecies cultures are incredibly rare in the oral cavity, which typically has a
large and diverse microbiome. Therefore, to increase the experimental relevance,
multispecies broth cultures were grown. This experiment was meant to determine
whether amixicile could specifically inhibit anaerobic bacteria in a multispecies
environment. To create a final OD600 0.3, equal amounts of P. gingivalis W83, P.
intermedia 17, A. actinomycetemcomitans, F. nucleatum, T. forsythia, and S. gordonii were
mixed. Growth of cultures in media with 10 µg/mL amixicile or metronidazole was
compared to untreated cultures at 48 hours. DNA was isolated from each culture and
the relative amount of bacteria was measured through qPCR analysis. Amixicile was
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Figure 9. Effect of saliva or serum on the inhibition of anaerobic bacteria by
amixicile. Overnight cultures of bacterial strains: (a) P. gingivalis W83, (b) P. intermedia
OMA 14, (c) A. actinomycetemcomitans 33384, (d) F. nucleatum 25586, (e) T. forsythia
43037, and (f) S. gordonii 10558 were diluted to OD600 0.05 and combined in BHI. This
multispecies culture was grown for 24 hours anaerobically at 37°C in BHI either
unsupplemented or supplemented with either 10% filtered human saliva or 10%
filtered human serum, untreated or with 0.5, 1, or 5 µg/mL amixicile. Genomic DNA
was isolated from each condition and qPCR was performed with the primers in Table
2. Ct values were converted to absolute fold change, where any positive change was
represented as values more than +1 and any negative change was proportionally
converted to values less than -1, between the amixicile-treated samples and untreated
controls of each media. Results are shown as mean ± SD of the amixicile-treated
sample compared to the untreated control from triplicate experiments. Statistical
analysis was done by ANOVA. *p<0.033, **p<0.002, and ***p<0.001 compared to the
untreated control.
Adapted from: Hutcherson JA, Sinclair KM, Belvin BR, Gui Q, Hoffman PS, Lewis JP.
Amixicile, a novel strategy for targeting oral anaerobic pathogens. Scientific Reports.
2017;7. doi: 10.1038/s41598-017-09616-0.
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still able to significantly inhibit growth of PFOR-containing bacteria in the mixed
culture (Figure 8). The metronidazole control acted in a similar fashion, though neither
antibiotic affected S. gordonii or A. actinomycetemcomitans growth. This confirms that
both antibiotics are selective for PFOR-containing anaerobic bacteria, including P.
gingivalis, P. intermedia, F. nucleatum, and T. forsythia, even in a multispecies culture.

Amixicile shows similar inhibition in the presence of saliva and serum.
Many niches in the oral cavity contain either saliva or gingival crevicular fluid,
which is incredibly similar to serum. To assess whether those factors could affect the
activity of amixicile, multispecies cultures were prepared as before in the presence or
absence of 10% saliva or serum. qPCR analysis was used to determine the relative
amount of bacteria in each sample. A. actinomycetemcomitans and S. gordonii both had less
than 1.4-fold increases or decreases in the amount of bacteria in each sample. Generally
in qPCR, any difference less than 2-fold is considered biologically insignificant.
Therefore, neither A. actinomycetemcomitans nor S. gordonii growth was affected by the
presence of the antibiotic, saliva, or serum (Figures 9c,f). P. gingivalis W83 and T.
forsythia were similarly inhibited in a dose dependent manner in all three conditions
(Figures 9a,e). P. intermedia, which in previous experiments required a higher dose of
amixicile than other periodontal pathogens to be inhibited, continued that trend. Here
the highest dose, 5 µg/mL significantly inhibits growth in all three types of media,
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Figure 10. Amixicile inhibits anaerobic monospecies biofilm maturation. (a) P.
gingivalis 33277, (b) P. intermedia 17, (c) A. actinomycetemcomitans, (d) F. nucleatum, (e) T.
forsythia, and (f) S. gordonii 10558 were grown as biofilms in BHI at 37°C anaerobically
for 24 hours. Biofilms were washed and fresh media was added containing no antibiotic
or supplemented with 1, 5, or 10 µg/mL amixicile. Clindamycin at 10 µg/mL was used
as a control. These were then incubated at 37°C anaerobically for an additional 24
hours. Crystal violet was used to stain the biofilms and they were measured at OD550.
Results are shown as mean ± SD compared to the 48 hour untreated control from
triplicate experiments. Statistical analysis was done by ANOVA. *p<0.033, **p<0.002,
and ***p<0.001 compared to the untreated control.
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however, 1 µg/mL causes less significant inhibition in BHI (Figure 9b). F. nucleatum
seems more resistant to the action of amixicile in saliva, but there is still a statistically
significant decrease in the amount of bacteria present compared to untreated controls
(Figure 9d). These results indicate that the efficacy of amixicile will not be negatively
affected by the saliva or serum present in the oral cavity.

Amixicile is able to prevent further biofilm growth of anaerobic bacteria.
Oral bacteria often form biofilms in the mouth, particularly on the tooth surface.
This is known as dental plaque and it provides a protective environment for the
bacteria. It has been shown that many antibiotics have decreased efficacy on bacteria
within a biofilm. Here we grew a monospecies biofilm for 24 hours and then exposed it
to amixicile for an additional 24 hours. S. gordonii and A. actinomycetemcomitans are not
susceptible to amixicile and as such, biofilm growth is not inhibited compared to the
untreated control (Figures 10c,f). However, P. intermedia, F. nucleatum, and T. forsythia
had inhibited biofilm growth with as low as 1 µg/mL amixicile, bringing the biofilm
level down to the 24 hour control and also showing similar efficacy to clindamycin
(Figures 10b, d, e). P. gingivalis, with 5 µg/mL amixicile, does not show further growth
from the 24 hour time point, indicating growth of the biofilm is inhibited with the
antibiotic (Figure 10a). Under 10 µg/mL amixicile, the amount of biofilm is even less
than the 24 hour control, indicating that amixicile was able to reduce the biofilm.

55

These data show that amixicile could be successful at preventing growth of new
biofilms as well as breaking down existing biofilms of pathogenic bacteria while not
affecting the healthy microbiome.

In multispecies biofilms, amixicile only inhibits anaerobic bacteria.
Oral biofilms are formed from a diverse group of oral bacteria, containing both
members of a healthy microbiome and pathogenic organisms. The biofilm is
notoriously hard to treat because the variety of microbes often provide protection for
each other, in both a physical manner, and with differential regulation. In this
experiment we formed a multispecies biofilm for four days and then left it untreated or
treated it with amixicile or metronidazole at 10, 20, or 50 µg/mL. Biofilm genomic
DNA was isolated for qPCR analysis with the primers in Table 2. P. gingivalis, P.
intermedia, F. nucleatum, and T. forsythia were all significantly inhibited by both amixicile
and metronidazole, even at the lowest concentration, 10 µg/mL (Figure 11). Neither
amixicile nor metronidazole inhibited A. actinomycetemcomitans or S. gordonii at any
concentration (Figure 11). This shows that even within a biofilm, both amixicile and
metronidazole selectively target the anaerobic PFOR-containing organisms.

Amixicile shows bactericidal activity similar to metronidazole.
The mechanism of action of amixicile works by inhibiting the activity of PFOR
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Figure 11. In a multispecies biofilm, amixicile inhibits growth of anaerobic
bacteria. Multispecies biofilms were grown by first growing a lawn of S. gordonii and
then adding the remaining bacteria 24 hours later. On day four, media was replaced
with BHI supplemented with (a) 10, (b) 20, or (c) 50 µg/mL amixicile or
metronidazole, while keeping an untreated control separately. Biofilms were incubated
through day nine, replacing media every 24 hours. Biofilms were collected and genomic
DNA was isolated for qPCR. Ct values were converted to absolute fold change, where
any positive change was represented as values more than +1 and any negative change
was proportionally converted to values less than -1. Results are shown as mean ± SD
compared to the untreated control from triplicate experiments. Statistical analysis was
done by ANOVA. *p<0.033, **p<0.002, and ***p<0.001 compared to the untreated
control.
Adapted from: Hutcherson JA, Sinclair KM, Belvin BR, Gui Q, Hoffman PS, Lewis JP.
Amixicile, a novel strategy for targeting oral anaerobic pathogens. Scientific Reports.
2017;7. doi: 10.1038/s41598-017-09616-0
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through binding the cofactor, TPP. This reduces the amount of energy in the cell. We
performed LIVE/DEAD staining to determine if this MOA acts in a bacteriostatic or
bactericidal manner. As the concentration of antibiotic increased, the number of cells
in the culture decreased. The red stain, propidium iodide, is only able to enter cells
with a broken membrane, and therefore indicates dead cells. The green stain shows the
live cells and a yellow color, when both stains are present in the same cell, still
indicates cell death. Heat was used as a control to kill all the cells, as can be seen at
both 2 and 24 hours (Figure 12). Clindamycin was used at 10 µg/mL to serve as a
bacteriostatic control. As such, most of the cells are still green at 2 and 24 hours,
though the total number of cells is still diminished. Metronidazole acted as the
bactericidal control, where most of the cells were still green at 2 hours, but over time,
there was an increase in dead cells in the culture. Amixicile, at the highest
concentration, followed a pattern similar to metronidazole, indicating that the lack of
energy in the cells is lethal over time. This shows that amixicile works similarly to
metronidazole.

Discussion
The oral microbiome can easily change composition from a healthy state to a
disease state when proper oral hygiene is ignored or certain risk factors are present. It
is much harder to force the microbiome back to a healthy state. Often the healthy state
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Figure 12. LIVE/DEAD staining indicates bactericidal mechanism of action. (a) P.
intermedia 17 cultures were grown with no antibiotic or with 1, 5, or 10 µg/mL
amixicile. 10 µg/mL clindamycin or metronidazole served as positive controls,
alongside heat killing. Representative fluorescence microscopy images from 0, 2, and
24 hours are shown. The green stain indicates living cells while the red or yellow color
indicates dead cells. All cells in the frame were manually counted to determine whether
they were live or dead. (b) The total number of cells counted for this experiment, with
the number of living cells in parentheses. (c) The percentage of live cells based on the
total number counted.
Adapted from: Hutcherson JA, Sinclair KM, Belvin BR, Gui Q, Hoffman PS, Lewis JP.
Amixicile, a novel strategy for targeting oral anaerobic pathogens. Scientific Reports.
2017;7. doi: 10.1038/s41598-017-09616-0.
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consists of Gram-positive organisms including streptococcal spp., while Gram-negative
anaerobes are often present in the disease state 14. These pathogenic organisms can
shift the microbiome even when present at low levels to begin the course of
periodontal disease 16,18,85.

Amixicile is a strong candidate for a novel therapeutic or even preventative
solution to periodontal diseases. PFOR is widely conserved in a variety of anaerobic
bacteria, indicating it would be a good target for therapy. We showed that in both
mono- and multispecies broth experiments, amixicile is able to target Gram-negative
anaerobic bacteria while not affecting Gram-positive facultative anaerobes. Even at low
concentrations of amixicile, it was effective against P. gingivalis, P. intermedia, F.
nucleatum, and T. forsythia. In some experiments, there was slight inhibition of A.
actinomycetemcomitans. While it does not contain PFOR and was not expected to be
affected by amixicile, nitazoxanide and amixicile have been reported to have a slight
effect on some non-PFOR-containing bacteria 86,87. Further, in studies with saliva or
serum, the inhibitory activity of amixicile was not affected, showing that it is still
viable in more in vivo-like conditions.

In order to increase the similarity to in vivo conditions, we studied the effect of
amixicile in biofilms as well. In monospecies biofilms, 1 or 5 µg/mL was sufficient to
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reduce growth. Slightly higher doses of 10, 20, and 50 µg/mL amixicile were effective
at inhibiting the Gram-negative anaerobes in the multispecies biofilms. The lowest
dose, 10 µg/mL, would be a dose of 500 mg for an average adult, well within reason for
a clinical dose.

Taking all of this together, amixicile could be used to eliminate the pathogenic
species in the oral cavity while keeping the healthy microbiome intact. Additionally,
there has been no sign of antibiotic resistance to nitazoxanide 83, indicating that the
unique MOA of this class of antibiotic may be unlikely to allow resistance to form.

Bacteria involved in periodontal diseases have also been associated with some
systemic diseases 88 and some cancers 89,90. So the therapeutic value of amixicile likely
stretches beyond periodontal disease. Mechanical treatments are currently relied upon
to remove the majority of dental plaque in order to reduce disease. This scaling and
root planing can be used in coordination with antibiotics in severe cases. The antibiotic
therapy is promising, but not with the current antibiotics on the market. As stated
previously, clindamycin is broad-spectrum and metronidazole has high toxicity, leading
both to be used less regularly. Amixicile would fit in the gap where a selective nontoxic antibiotic is needed in order to provide non-mechanical options to limit the need
for periodontal surgery. It has been shown to be non-toxic in animal models well above
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a clinical dose, is readily absorbed, and concentrates in areas of inflammation 31. In all
of our studies, amixicile had similar inhibitory activity to metronidazole. Given the lack
of toxicity and the ability to accumulate in areas of inflammation while not affecting
healthy tissue, amixicile is the logical next step in the treatment of periodontal disease.
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Chapter 4: Drosophila melanogaster innate immunity in response to oral microbes.

Introduction
It is thought that the immune response plays as large a role in the symptoms of
periodontal disease as the diseased microbiome 23. Both the innate and adaptive
immune systems are part of this reaction in different ways. The innate immune
response consists of neutrophils, macrophages, and pathways, including complement,
that respond in a general form to infection, unlike adaptive immunity, which creates a
specific response to a foreign substance. Immune cells have been shown to localize in
periodontal pockets to attempt to subdue the infection. However, they are often prone
to apoptosis, which acts to release a variety of nutrients into the area, which the
bacteria can then use to survive and replicate.

In this way, periodontal diseases are cyclic, and either the infection must be
eliminated, the immune response diminished, or both, in order to successfully reduce
the disease symptoms. The innate immune response acts, in part, by activating NF-κB
signaling. In Drosophila, this signaling leads to the amplification of antimicrobial
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Figure 13: The Imd and Toll pathways in Drosophila melanogaster showing
knockout mutations. The Imd pathway recognizes DAP-type peptidoglycan on Gramnegative bacteria through the PGRP-LC receptor. The death domain on Imd is signaled
and then activates TAB2 and TAK1. The IKK β/γ signalosome is then activated to
phosphorylate Relish. Finally, Relish translocates to the nucleus and transcribes
antimicrobial peptides (AMPs) by activating NF-κB, including attacin, cecropin,
defensin, diptericin, and drosocin. The Toll pathway responds to Gram-positive
bacteria through Spätzle recognizing Lys-type peptidoglycan. Toll activates MyD88,
Tube, and Pelle in order to degrade Cactus, which allows Dif and Dorsal to localize to
the nucleus, activating NF-κB, and upregulating transcription of antimicrobial peptides
including cecropin, defensin, drosomycin, and metchnikowin. Canton-S and Y,w are
two commonly used wild type flies that have normal functioning Toll and Imd
pathways. Additionally, we used three mutant strains, where proteins throughout
these pathways are inactivated, shown underlined and starred in the figure. The Spz
mutant has defective Spätzle protein and the Imd mutant has a defect in Imd. The Key
mutant has inactive Kenny protein, which helps make up the IKK signalosome.
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peptides, which then act to decrease the bacterial infection (Figure 13). In these
experiments, we identify which components of the NF-κB signaling pathways are
upregulated in varied mono- or multispecies infections to determine the differences in
the response to periodontal pathogens compared to normal oral microflora. Three
knockout mutants are used in this study in order to further separate the roles of the
Imd and Toll pathways. The Canton-S wild type is the background for the Spz
homozygous mutant, which would eliminate the functional Toll pathway, preventing
activation of AMPs to combat Gram-positive infections (Figure 13). Similarly, CantonS is the background for the Imd homozygous knockout, which should eliminate the
function of the Imd pathway, preventing the flies from responding to Gram-negative
infections (Figure 13). There is also a second wild type used in these experiments, Y,w,
which is the background for the Key homozygous mutant, which also inactivates the
Imd pathway (Figure 13). Through these studies, we found that both pathways, Toll
and Imd, play a role in responding to these oral microbes. Clarifying the immune
response to periodontal pathogens could allow a two-pronged therapeutic approach to
periodontal disease, which decreases the bacterial load and also decreases the immune
overreaction.

Results
Periodontal bacteria are capable of surviving microaerobic environments.
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Figure 14: Anaerobic bacterial growth under microaerobic conditions. Bacteria
were grown overnight at 25, 30, or 37°C with the oxygen level at 0% or 6%. The black
line indicates the starting OD600 of the culture, 0.05. The error bars indicate technical
triplicate. Statistical analysis was done by ANOVA. All columns are compared to the
0% O2, 37°C control. *p<0.033, **p<0.002, and ***p<0.001 compared to the untreated
control.
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Anaerobic oral bacteria and S. gordonii, a facultative anaerobe, were grown in
anaerobic conditions, 0% O2 at 37°C, as well as in aerobic conditions, with 6% O2 or at
lower temperatures, 25°C and 30°C, overnight. These bacteria are all capable of
growing anaerobically, and they have shown varying levels of aerobic tolerance 91-93. S.
gordonii grew very well under all conditions (Figure 14e). At 30°C in the presence of
oxygen, P. gingivalis W83 and 77, P. intermedia OMA 14, and F. nucleatum had
significantly reduced growth compared to the control, however, were still able to grow
(Figures 14a-d). P. gingivalis, P. intermedia, and F. nucleatum growth was mostly inhibited
at 25°C in 0% and 6% O2 (Figures 14a-d).

Consistent amounts of bacteria are injected in the Drosophila studies.
To inject the fruit flies, a sterile 30-gauge needle was dipped in OD600 3.0
bacterial culture and then inserted into the thorax, just enough to puncture the cuticle
and deliver the bacteria into the hemocoel (body cavity). Since this method is not
exact, the consistency of the injections needed to be determined. All data shown was
calculated by subtracting uninfected fly counts from infected fly counts. There seemed
to be significant variation between the amounts of different bacteria injected. P.
gingivalis W83 was consistently higher than the other species (Table 3). The standard
deviation was high for some samples but was proportional to the CFU/fly values,
typically around 10%. Since the 6-Species culture is equal parts each strain, adding
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Table 3: Colony-forming units of bacteria injected per fly.
Bacteria
CFU/fly
Porphyromonas gingivalis W83
5813
Porphyromonas gingivalis 33277
723
Prevotella intermedia 17
161
Prevotella intermedia OMA 14
390
Aggregatibacter actinomycetemcomitans 33384
288.5
Fusobacterium nucleatum 25586
155
Tannerella forsythia 43037
46.5
Streptococcus gordonii 25586
477.5
Streptococcus mitis 49456
504.3
6-Species (Pg 77, Pi OMA 14, Aa, Fn, Tf, Sg)
356.7
7-Species (Pg 77, Pi OMA 14, Aa, Fn, Tf, Sg, Sm)
368
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St Dev
±393.1
±112.5
±11.6
±44
±4.1
±17.5
±7.6
±142.4
±74.8
±19.7
±30.3

the CFU/fly values for all six individual cultures and then dividing by six should be
approximately equal to the CFU/fly value for the 6-Species culture. The same applies
to the 7-Species culture. Since the values are close in both cases, it indicates that the
experiment was successful and the amount of bacteria injected is generally consistent.

Periodontal bacteria have different virulence in Drosophila than in the oral cavity.
We injected wild type Drosophila (Canton-S) with mixed bacterial cultures to
assess which cultures caused lethality. The flies were observed for one week to
determine the percentage of flies dying. Generally, the injections were well tolerated by
the flies, and due to the minimal damage to the cuticle, they survived the initial
injection and wound healing. Throughout the week, the mock-infected flies, which
were injected with media only, survived at 92%. The Gram-positive streptococcus spp.
did show significant lethality compared to the mock infection, with only 6-12% of flies
surviving (Figure 15). The multispecies cultures had a lethality of 96-100%, which was
not unexpected, given that most of the monospecies cultures showed high lethality,
above 50%. The Porphyromonas gingivalis strains, W83 and 77, showed 28 and 8%
survival, respectively (Figure 15). The Prevotella intermedia strains, 17 and OMA 14,
showed 18 and 48% survival, respectively (Figure 15). The other species we used that
are involved in oral infections, A. actinomycetemcomitans, F. nucleatum, and T. forsythia,
showed much lower lethality than P. gingivalis and P. intermedia (Figure 15). A.
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Figure 15: Kaplan-Meier curves for Drosophila Canton-S survival under monoand multispecies bacterial infections. Twenty 3-5 day old female flies were either
mock-injected with BHI or injected with bacterial cultures (6-Species, 7-Species, Aa, Fn,
Pg W83, Pg 77, Pi 17, Pi OMA 14, Sg, Sm, Tf). Survival was measured every 12 hours for
seven days. The data is shown from triplicate experiments. The survival rate was
significantly different for each infection compared to mock. p<0.05.
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actinomycetemcomitans showed only 30% lethality (Figure 15), while F. nucleatum killed at
28% (Figure 15), and T. forsythia at 33% (Figure 15). Two wild type strains and three
mutant strains of Drosophila were also studied for survival. Canton-S is a commonly
used wild type strain in fruit fly research. Both the Imd-/- and Spz-/- mutant flies were
created from the Canton-S wild type background. Y,w is a different wild type, which
was used to create the Key-/- mutant. The flies were either mock-injected or injected
with a 7-Species bacterial culture. Imd-/- and Spz-/- are both homozygous mutants
created from the Canton-S wild type fly. The wild type Canton-S was the most resistant
to bacterial killing of the three fly strains. The mock-infected flies had over 90%
survival, while the 7-Species bacterial culture caused lethality between 50 and 80%
(Figure 16a). Key-/- is a homozygous mutant fly created from the Y,w wild type strain.
Both strains had over 90% survival of mock-infected flies and 100% lethality in the 7Species infected flies (Figure 16b). However, the Y,w wild type had slightly delayed
lethality compared to the Key-/- mutant (Figure 16b).

Both the Imd and Toll pathways are activated in multispecies infections.
We injected five fly lines (Canton-S, Imd-/-, Spz-/-, Y,w, Key-/-) with either BHI or
a 7-Species bacterial culture containing Pg 77, Pi OMA 14, Aa, Fn, Tf, Sg, and Sm. The
flies were removed at 2 or 24 hours post-infection for gene expression analysis. Imd is
at the beginning of the Imd pathway and regulates the expression of Attacin, Cecropin,
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Figure 16: Kaplan-Meier curves for Drosophila mutant survival under
multispecies bacterial infections. Twenty 3-5 day old female flies of each strain
(Canton-S, Imd-/-, Spz-/-, Y,w, Key-/-) were either mock-injected with BHI or injected
with a 7-Species bacterial culture. Survival was measured every 12 hours for 7 days.
The data is shown from triplicate experiments. The survival rate was significantly
different for each infection compared to mock. p<0.05.
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Defensin, Diptericin, and Drosocin. Imd expression was upregulated in both wild type
flies, Canton-S and Y,w, when infected, at the 2 and 24 hour time points (Figure 17a).
The Imd and Key mutants do not show differential regulation of Imd at either time
(Figure 17a). The Spz mutant has slightly upregulated Imd at 2 hours and
downregulated Imd at 24 hours post-infection (Figure 17a). Attacin, Diptericin, and
Drosocin are all upregulated in both wild type flies, compared to the mock-infected
flies, particularly at 24 hours post-infection (Figures 17b-d). These AMPs are not
upregulated due to infection in the Imd pathway mutants (Imd-/- and Key-/-), verifying
that the Imd pathway is not functional with these mutations (Figures 17a-d). The Spz
mutant does show upregulation of these AMPs, though significantly less than the
Canton-S wild type.

Toll is at the beginning of the Toll pathway and regulates Cecropin, Defensin,
Drosomycin, and Metchnikowin. Toll is actually downregulated in Canton-S compared
to the mock-infected flies and at 24 hours in the Spz and Key mutants (Figure 18a). It
is slightly upregulated in Imd-/- and Y,w. Due to the standard deviation, the Spz mutant
at 2 hours shows no differential regulation due to infection (Figure 18a). Drosomycin
and Metchnikowin are significantly upregulated in Imd-/- and Y,w at the 24 hour time
point (Figures 18b,c). The Canton-S flies showed slight upregulation, compared to
mock-infected flies, in Drosomycin at 24 hours and Metchnikowin at 2 and 24 hours
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Figure 17: Imd pathway-controlled innate immune response to multispecies
bacterial infections. 3-5 day old female flies of each species were either mock-injected
with BHI or injected with a 7-Species mixed culture. They were incubated at 30°C for
either 2 or 24 hours. RNA was isolated and qPCR was performed using primers to
specific genes involved in the innate immune response in Drosophila. Ct values were
converted to absolute fold change, where any positive change was represented as values
more than +1 and any negative change was proportionally converted to values less
than -1. The data is shown from triplicate experiments. Statistical analysis was done by
ANOVA. Imd-/- and Spz-/- are compared to the Canton-S control, time matched. Key-/- is
compared to the Y,w control, time matched. *p<0.033, **p<0.002, and ***p<0.001.
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(Figures 18b,c). Drosomycin is significantly upregulated in Key-/- at both time points
and Metchnikowin is significantly upregulated at 2 hours and downregulated at 24
hours in the same flies. Finally, Spz-/- has a defective Toll pathway due to the lack of
spätzle, so both Drosomycin and Metchnikowin are downregulated (Figures 18b,c).

Cecropin and Defensin are controlled by both pathways. Cecropin is
upregulated, compared to mock-infected, at both time points in Canton-S, Y,w, Imd-/-,
and Spz-/- (Figure 19a). It shows no differential regulation in the Key mutant compared
to the mock-infected flies but is significantly downregulated from the Y,w wild type.
Defensin is only significantly upregulated due to infection in the short term in Y,w and
is downregulated in the long term in Key (Figure 19b). Hop is involved in the
JAK/STAT pathway and only shows significant upregulation due to infection in
Canton-S (Figure 20). Imd-/-, Spz-/-, and Key-/- show downregulation compared to the
associated wild type immune response (Figure 20).

Discussion
This study was conducted to determine how innate immunity responds to
bacterial challenge by periodontal pathogens. Using the Drosophila model to study the
interaction between the host and anaerobic bacteria is a fairly new concept 68,94,95. The
fly is not an ideal host for anaerobic bacteria due to the aerobic environment and

78

Figure 18: Toll pathway-controlled innate immune response to multispecies
bacterial infections. 3-5 day old female flies of each species were either mock-injected
with BHI or injected with a 7-Species mixed culture. They were incubated at 30°C for
either 2 or 24 hours. RNA was isolated and qPCR was performed using primers to
specific genes involved in the innate immune response in Drosophila. Ct values were
converted to absolute fold change, where any positive change was represented as values
more than +1 and any negative change was proportionally converted to values less
than -1. The data is shown from triplicate experiments. Statistical analysis was done by
ANOVA. Imd-/- and Spz-/- are compared to the Canton-S control, time matched. Key-/- is
compared to the Y,w control, time matched. *p<0.033, **p<0.002, and ***p<0.001.
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growth of the flies at 25°C. However, the periodontal pathogens we work with do show
some aerobic tolerance. F. nucleatum and P. intermedia have shown aerobic tolerance up
to and even longer than a full day 91,93. T. forsythia has shown aerotolerance for only a
few hours 92. P. gingivalis has been previously studied in D. melanogaster and it was found
to persist for up to 60 hours and cause lethality 68. Due to this evidence, we moved
forward with the Drosophila model. First, we determined that the bacteria we were
working with did show growth at suboptimal temperatures in a slightly aerobic
environment. All of the bacteria used in this study grew at least slightly at 30°C in 6%
oxygen. This showed that the bacteria did have a good chance of persisting long
enough in the fly to induce an immune response and cause lethality.

We followed up with survival studies with the different bacteria as well as the
multispecies cultures. P. gingivalis, P. intermedia 17, and S. gordonii killed a large
percentage of wild type D. melanogaster. P. intermedia OMA 14 was less virulent, killing
only half of the flies. Finally, A. actinomycetemcomitans, F. nucleatum, and T. forsythia were
only slightly virulent in the flies. However, all infections led to significantly increased
death compared to the mock-infected. Interestingly, these patterns are not along the
lines of which bacteria are important in periodontal disease and which are considered
healthy bacteria in the oral cavity. Streptococcus species are considered beneficial in the
oral cavity yet they are virulent in Drosophila 96. The other bacteria are common in
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Figure 19: Imd- and Toll-controlled innate immune response to multispecies
bacterial infections. 3-5 day old female flies of each species were either mock-injected
with BHI or injected with a 7-Species mixed culture. They were incubated at 30°C for
either 2 or 24 hours. RNA was isolated and qPCR was performed using primers to
specific genes involved in the innate immune response in Drosophila. Ct values were
converted to absolute fold change, where any positive change was represented as values
more than +1 and any negative change was proportionally converted to values less
than -1. The data is shown from triplicate experiments. Statistical analysis was done by
ANOVA. Imd-/- and Spz-/- are compared to the Canton-S control, time matched. Key-/- is
compared to the Y,w control, time matched. *p<0.033, **p<0.002, and ***p<0.001.
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diseased biofilms but only some of them are virulent in the flies. We also looked at the
virulence of multispecies infections in wild type flies compared to flies with deficient
Imd and Toll pathways. The mock-infected flies all had high survival. There was almost
no difference in the virulence of the multispecies infections in the Y,w flies compared
to the Key-/- mutant and they both reached complete lethality. However, the Imd-/- and
Spz-/- mutants died faster than the Canton-S flies at 1.5x (CI=0.96-2.20) and 1.8x
(CI=1.19-2.69) faster, respectively.

The causes of the lethality due to bacterial infection in the flies are likely multifaceted. The symptoms and host responses reacting to the infections in periodontal
disease are similarly so. One important component of periodontal disease is the
immune response. It contributes at least as much to the disease as toxicity from the
bacterial infections. In order to fully reduce the symptoms of periodontal disease, both
aspects need to be addressed. However, the host/pathogen interactions are poorly
understood. The Drosophila model system allows us to clarify the innate immune
response without interference from an adaptive immune response. We examined the
immune response, based on gene expression, of the fruit flies to the variety of bacteria
in the study as well as to multispecies infections.

Five types of flies were studied, two wild types and three mutants formed from
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Figure 20: JAK/STAT pathway-controlled innate immune response to
multispecies bacterial infections. 3-5 day old female flies of each species were either
mock-injected with BHI or injected with a 7-Species mixed culture. They were
incubated at 30°C for either 2 or 24 hours. RNA was isolated and qPCR was performed
using primers to specific genes involved in the innate immune response in Drosophila.
Ct values were converted to absolute fold change, where any positive change was
represented as values more than +1 and any negative change was proportionally
converted to values less than -1. The data is shown from triplicate experiments.
Statistical analysis was done by ANOVA. Imd-/- and Spz-/- are compared to the CantonS control, time matched. Key-/- is compared to the Y,w control, time matched.
*p<0.033, **p<0.002, and ***p<0.001.
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those wild type strains. The Imd-/- and Key-/- mutants both contain mutations in genes
involved in the Imd immune response pathway. In flies, this pathway responds to
Gram-negative bacterial infections by recognizing DAP-type peptidoglycan. The Spz
mutant, on the other hand, has a defect in the Toll pathway, which recognizes Grampositive bacterial infections by LYS-type peptidoglycan. The third immune pathway in
Drosophila is the JAK/STAT pathway, which primarily responds to viral infections. We
found that this pathway was not activated in response to the multispecies bacterial
injections.

The expression of Toll, the pathway receptor, was higher in the Imd-/- and Spz-/flies than the Canton-S wild type. The antimicrobial peptides controlled by only the
Toll pathway, Drosomycin and Metchnikowin, are both downregulated in the Spz-/flies, which have an inactive Toll pathway. Neither are upregulated in the Canton-S
wild type flies, compared to mock infections. They are upregulated in the Y,w wild
type, though only at 24 hours for Drosomycin. So the Toll pathway is, at least partially,
activated in response to the multispecies injections, which did contain Gram-positive
bacteria.

Attacin, Diptericin, and Drosocin are exclusively under the control of the Imd
pathway. These all show upregulation compared to the mock-infected flies in the wild
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type strains, though Drosocin only at 24 hours. The upregulation of these is
dramatically decreased in the mutant flies, particularly in Imd-/- and Key-/- with the
inactive Imd pathway. Cecropin and Defensin show more of a mixed response, likely
due to the fact that they can be regulated by either pathway.

These results do show an interesting pattern, indicating that both the Toll and
Imd pathways are important in responding to bacterial infections, yet in different ways.
However, this is still not a complete picture. These pathways solely recognize
peptidoglycan, which limits the information, given that in humans, bacteria can be
recognized due to a wide variety of PAMPs. This may have led to a lower total innate
immune response than would be seen in other model systems. RNA Sequencing would
be able to give a more complete idea of the total immune response. It would also be
helpful to conduct similar experiments in a variety of model organisms that have more
extensive bacterial recognition systems.
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Chapter 5: Conclusions

Periodontal diseases are complex in that they are attributed to multispecies
bacterial infections and also the host immune response. Many risk factors can also
contribute to the disease state. At this point, the treatments, though the disease is
widespread, are lacking. Antibiotic therapy and mechanical treatments have some effect
but often see a relapse into the diseased microbiome. Because of this, and the
economic burden of disease, it is important to find a better way to treat periodontal
diseases.

This study investigated the efficacy of amixicile on periodontal pathogens with
significant success. In mono- and multispecies cultures in both broth and biofilms, and
also in the presence of saliva or serum, amixicile selectively inhibited the Gramnegative anaerobic organisms without harming the Gram-positive facultative
anaerobes, including Streptococcus gordonii. In this way, amixicile would effectively
inhibit anaerobic bacteria that have been shown to contribute to periodontal diseases,
while leaving the healthy microbiome intact. Collected data from this and other studies
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indicate that amixicile is a better antibiotic than those currently used for treatment and
could even be developed for preventative care.

However, the bacterial infection is not the only component of periodontal
diseases. The lack of homeostasis in the host immune response leads to considerable
damage of the host tissues and bone. Components of both the innate and adaptive
immune responses are involved in the reaction to bacterial infections in periodontal
diseases but neither is fully understood. In the Drosophila model, we were able to study
the innate immune response in isolation, with a comparable system to mammalian
immunity. It was clear that both the Toll and Imd pathways contributed to the immune
response against the periodontal pathogens as both mono- and multispecies infections.

These experiments could lead to a potential therapy for periodontal disease,
possibly a two-pronged approach, with a selective antibiotic targeting the pathogenic
bacteria along with a therapeutic to decrease NF-κB signaling. This would halt the
cyclic progression of periodontal disease by reducing both causes of symptoms and
would allow the oral cavity to heal.
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Chapter 6: Future Perspectives

It is currently unknown whether the reduction of pathogenic bacteria in the oral
cavity from amixicile would be sufficient to halt the disease progression and reduce the
symptoms. Since these symptoms result from both the bacterial infection and the host
immune response, more research would need to be done. It is possible that the simple
reduction of the pathogenic pro-inflammatory anaerobic bacteria targeted by amixicile
would also successfully reduce the immune response. Ideally, experiments would be
repeated in alternative model systems, where the effect of amixicile on both the
bacterial infection and the immune response could be studied concurrently. HL-60 cells
(neutrophil precursors) and neutrophils could be used to identify whether amixicile is
able to reduce the immune response, since neutrophils are abundantly present in
periodontal pockets. Mouse models could then be studied in order to see whether the
symptoms of periodontal disease change significantly with the amixicile treatment.

Amixicile is also still being studied in the lab using patient biofilms, both
healthy and diseased, in order to corroborate the findings that it is selective against
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anaerobic bacteria, even in a much more complex microbiome. RNA sequencing is
being done to identify the known and previously uncharacterized bacteria present in
the patient samples to determine which are downregulated under the amixicile
therapy.

Amixicile is currently in pre-clinical trials for the treatment of Clostridoides
difficile infections and could be expanded to periodontal disease treatment as well.
According to the data available, it seems that amixicile is very unlikely to induce
resistance and, as such, could even be used in a preventative manner. Testing the
antibiotic in toothpastes or mouthwashes could show a significant decrease in the
development of periodontal disease. We hope that this future experimentation will lead
to amixicile being used as either a preventative therapy or treatment option for
individuals at risk for periodontal disease.
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